ClearPoint Neuro Announces Exclusive Multi-Year Licensing Agreement with UCSF for Innovative Intra-Cerebral Cellular Delivery Platform
SOLANA BEACH, Calif., March 28, 2023 (GLOBE NEWSWIRE) -- ClearPoint Neuro, Inc. (NASDAQ: CLPT) (the “Company”), a global therapy-enabling platform company providing navigation and delivery to the brain, today announced an exclusive multi-year licensing agreement of intellectual property from UC San Francisco (UCSF) through its Innovation Ventures group to develop and commercialize a radially branching cellular delivery device for use both in the Operating Room under fluoroscopy/CT guidance and under MRI guidance.
“This invention will help clinicians guide the delivery of biologic therapies — from stem cell transplants to gene therapy vectors — to specific locations in the human brain with real-time image guidance,” said Dr. Daniel Lim, MD, PhD, Professor of Neurological Surgery at UCSF. “By helping surgeons tailor biologic delivery to individual patient anatomy and specific diseases, I hope that this invention can contribute importantly to the successful treatment of neurological disorders such as Parkinson’s disease.” Dr. Lim and colleagues published preliminary pre-clinical results in Molecular Therapy demonstrating successful deposition of cells to multiple targets using the radially branched deployment device in the MRI, guided by the ClearPoint Neuro Navigation platform.1
UCSF’s Innovation Ventures group leads business development and licensing efforts on behalf of UCSF. Under the terms of the agreement, the Company will develop, obtain regulatory clearance, and commercialize in key geographies the intracerebral cellular delivery device designed by Dr. Lim.
“Technical limitations of devices and surgical strategies to successfully deliver therapeutic agents to precise targets have plagued cell therapy trials for decades,” stated Jeremy Stigall, Executive Vice President and GM of Biologics and Drug Delivery at ClearPoint Neuro. “We are delighted to partner with UCSF to bring this innovative delivery platform to our pharmaceutical partners working on cellular therapy. We believe that, when combined with our ClearPoint system and software, Dr. Lim’s exciting cell delivery platform could potentially empower predicable and precise delivery of cells into different anatomical targets using various image-guidance technologies. This innovative approach will allow cellular delivery at facilities that do not have access to MRI and will also expedite therapeutic delivery and ultimately patient recovery.”
About ClearPoint Neuro
ClearPoint Neuro’s mission is to improve and restore quality of life to patients and their families by enabling therapies for the most complex neurological disorders with pinpoint accuracy. Applications of the Company’s current product portfolio include deep brain stimulation, laser ablation, biopsy, and delivery of drugs, biologics, and gene therapy to the brain. The ClearPoint® Neuro Navigation System has FDA clearance, is CE-marked, and is installed in more than 65 sites in North America, Europe, and South America. ClearPoint Neuro is partnered with more than 50 biologics/pharmaceutical companies, academic centers, and contract research organizations, providing solutions for direct CNS delivery of therapeutics in pre-clinical studies and clinical trials worldwide. To date, more than 6,000 procedures have been performed and supported by the Company’s field-based clinical specialist team, which offers support and services to our customers and partners. For more information, please visit www.clearpointneuro.com.
Forward-Looking Statements
Statements in this press release concerning the Company’s plans, growth and strategies may be forward-looking statements within the context of the federal securities laws. Statements regarding the Company's future events, developments and future performance, the size of total addressable markets or the market opportunity for the Company’s products and services, as well as management's expectations, beliefs, plans, estimates or projections relating to the future, are forward-looking statements within the meaning of these laws. Uncertainties and risks may cause the Company's actual results to differ materially from those expressed in or implied by forward-looking statements. Particular uncertainties and risks include those relating to: the impact of the COVID-19 pandemic, global instability, supply chain disruptions, labor shortages, and macroeconomic and inflationary conditions; future revenue from sales of the Company’s ClearPoint Neuro Navigation System and other new products offered by the Company; the Company’s ability to market, commercialize and achieve broader market acceptance for the Company’s ClearPoint Neuro Navigation System and other new products offered by the Company; the ability of our biologics and drug delivery partners to achieve commercial success, including their use of our products and services in their delivery of therapies; and risks inherent in the research, development, and regulatory approval of new products. More detailed information on these and additional factors that could affect the Company’s actual results are described in the “Risk Factors” section of the Company’s Annual Report on Form 10-K for the year ended December 31, 2022, which has been filed with the Securities and Exchange Commission.
1 Silvestrini MT, Yin D, Martin AJ, et al. Interventional magnetic resonance imaging-guided cell transplantation into the brain with radially branched deployment. Mol Ther. 2015;23(1):119-129. doi:10.1038/mt.2014.155
2 Funding for this research came, in part, from the California Institute for Regenerative Medicine (RT2-01975).
A video accompanying this announcement is available at: https://www.globenewswire.com/NewsRoom/AttachmentNg/69262df6-e6cf-4483-8de7-79e3f386b14d
To view this piece of content from www.globenewswire.com, please give your consent at the top of this page.To view this piece of content from ml.globenewswire.com, please give your consent at the top of this page.
About GlobeNewswire by notified
GlobeNewswire by notifiedGlobeNewswire by notified is one of the world's largest newswire distribution networks, specializing in the delivery of corporate press releases financial disclosures and multimedia content to the media, investment community, individual investors and the general public.
Subscribe to releases from GlobeNewswire by notified
Subscribe to all the latest releases from GlobeNewswire by notified by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from GlobeNewswire by notified
Nokia Corporation: Repurchase of own shares on 30.05.202330.5.2023 20:00:00 CEST | Press release
Nokia Corporation Stock Exchange Release 30 May 2023 at 21:00 EEST Nokia Corporation: Repurchase of own shares on 30.05.2023 Espoo, Finland – On 30 May 2023 Nokia Corporation (LEI: 549300A0JPRWG1KI7U06) has acquired its own shares (ISIN FI0009000681) as follows: Trading venue (MIC Code)Number of sharesWeighted average price / share, EUR*XHEL341,6973.84CEUX20,7733.85AQEU4,1303.85TQEX00.00Total366,6003.84 * Rounded to two decimals On 3 February 2022, Nokia announced that its Board of Directors is initiating a share buyback program under the authorization granted by Nokia’s Annual General Meeting on 8 April 2021 to return up to EUR 600 million of cash to shareholders in tranches over a period of two years. The second phase of the share buyback program in compliance with the Market Abuse Regulation (EU) 596/2014 (MAR), the Commission Delegated Regulation (EU) 2016/1052 and under the authorization granted by Nokia’s Annual General Meeting on 5 April 2022 started on 2 January 2023 and ends a
Kvalitena AB (publ) publicerar årsredovisning för 202230.5.2023 20:00:00 CEST | Pressemelding
Kvalitena publicerar årsredovisning för 2022. Bilagor kvalitenaab-2022-12-31-svKvalitena AB (publ) årsredovisning 2022
Report for the first quarter of 202330.5.2023 19:43:43 CEST | Press release
Oslo, 30 May 2023 Highlights in the period Gross production in Q1 2023 decreased 21% compared to Q4 2022.In January 2023, the Company timely paid accrued and due interest on its corporate bond. Early in February 2023, the Company was notified of the formal approval to its acquisition of the 8.34% participating interests in five concessions in Santa Cruz, Argentina where the Company also serves as operator. The Company has worked with the relevant Provincial authorities on the satisfaction of the requirements to restart full activities in the MMO and Cañadón Ramírez fields (Chubut, Argentina) and reopened such fields. For more information, please see enclosed Interoil Exploration and Production ASA's Report for the first quarter of 2023. This information is subject to the disclosure requirements pursuant to section 5 -12 of the Norwegian Securities Trading Act. *************************** Please direct any further questions to ir@interoil.no (mailto:ir@interoil.no) About Interoil Intero
Change in management30.5.2023 19:41:51 CEST | Press release
The board of directors and CEO/CFO Anders Fink Vadsholt has today entered into a severance agreement pursuant to which Mr. Vadsholt will step down as CEO/CFO of the Company. Regardless, Mr. Vadsholt will remain available for the company until his replacement has been found and all disputes related to the US security class action case has been finally settled, however, in no event longer than until 1 October 2023. Anders Fink Vadsholt states:” With the latest progress in our US security class action case described in company announcement of 17 April 2023, and a successful sale and hand over of all activities to Zevra Therapeutics (Previously Kempharm), I see my job as CEO/CFO successfully completed and the time has come for me to look for new challenges. I would like to thank all former colleagues in Orphazyme for years of dedicated work and loyalty”. Chairman Michael Hove states: On behalf of the board, I would like to thank Mr. Vadsholt for his dedicated work especially during the pas
Transfer of Harvia's own shares as rewards under the incentive program30.5.2023 19:35:00 CEST | Press release
Harvia Plc, Stock Exchange Release, May 30, 2023 at 8:35 p.m. EEST The Board of Directors of Harvia Plc has on 3 May 2023 decided on a directed share issue without consideration for the payment of rewards earned under the company’s share-based incentive program. The share payments concern the performance period 2020–2022 of the company’s share-based incentive program launched in 2020. In the share issue, 9,109 own shares held by the company have today been transferred without consideration to the key employees participating in the share-based incentive program in accordance with the program-specific terms and conditions. After the transfer of shares under the incentive program and the shares transferred at the same time as part of the board remuneration, the company holds a total of 9,637 own shares. The decision on the transfer of shares is based on the authorization granted to the Board of Directors by the Annual General Meeting on 20 April 2023. No new shares shall be issued in conn